CD79A and infection: Therapy was well-tolerated, and the patient reported no side effects, particularly no infusion reactions or infections, notwithstanding the decrease of IgA, IgG and IgM serum levels during anti-CD38 treatment (94 mg/dL pre-treatment → 16 mg/dL at month +16, 1,083 → 808 mg/dL, and 73 → 18 mg/dL, respectively).